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Continuous Glucose Monitoring and Diabetes Management During Pregnancy
Abstract
According to the Scope of Practice, Standards of Practice, and the Standards of
Professional Performance for Diabetes Educators, registered nurses play an integral role in the
promotion of diabetes self-management education and training in diabetes care (AADE, 2017).
This paper upholds the standards set forth by the American Association of Diabetes Educators
(2017) governing body, to stimulate the process of peer review, promote documentation of the
outcomes of diabetes self-management education and training (DSME/T), encourage research to
validate practice and improve quality DSME/T and diabetes care for pregnant women who use
continuous glucose monitoring. To improve registered nurse education and diabetes practice, the
Continuous Glucose Monitoring and Diabetes Management During Pregnancy Program was
presented to the management and leadership of a high-risk subspecialty unit of a major Northern
California healthcare maintenance organization. The implementation unit provided the staff,
resources, and interest needed to support the project. The information provided in this paper
discuss the needs assessment that was conducted as a basis for implementation of the pilot
project. The SWOT analysis and Work Breakdown Structure (WBS) are project management
tools that were utilized as part of the proposed Continuous Glucose Monitoring and Diabetes
Management During Pregnancy Program Doctor of Nursing project. The SWOT analysis
provides details about barriers to the project, support for the need, and objectives enacted to
overcome obstacles, and elicited sponsor, provider, and team member support. The WBS was
used as a communication tool to inform, update, and review progress to ensure the project was
completed on time and within budget. The budget forecasted the need of approximately
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$3,000.00 to successfully implement the project. The outcome measurement tool used to
determine the success of the project was qualitative data received from the registered nurses
upon completion of the CGM device training modules. Qualitative data was gathered from the
registered nurses using Qualtrics pre- and post-education and training. The secondary outcome
measurement tools were the latest lab result HgbA1c of <7.0 mg/dl and a reduction of
hypoglycemic episodes during pregnancy.
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Introduction
Diabetes and Pregnancy
Safely achieving near-normal blood glucose levels remain the primary goal of clinicians
who provide care for pregnant women with preexisting and gestational diabetes. However, the
number of women affected by preexisting diabetes has increased over the years, making
achieving near-normal blood glucose challenging due to many factors, including maternal
obesity. Since 2010 the United States has experienced an increase in prevalence of obesity by
17.8%; likewise, the upward trend of diabetes has seen a similar increase (Bhupathiaju & Hu,
2016). According to researchers (Bhupathiaju & Hu, 2016; Hunt & Schuller, 2007), obesity is a
major risk factor for type 2 diabetes, is considered a public health problem, and affects women
more than men. Researchers (Hunt & Schuller, 2007) suggests the incidence of diabetes
continues to rise, increasing the risk of diabetes during pregnancy of women in their childbearing years. The prevalence of gestational diabetes in a population reflects the prevalence of
type 2 diabetes in that population (Hunt & Schuller, 2007), due in part to women with gestational
diabetes being at a greater risk of converting to type 2 diabetes within five to 10 years of giving
birth (Kim, et al., 2002). Further, as the overall rate of obesity and diabetes have risen over the
years, so has the number of pregnant women with preexisting diabetes. From 2012-2016, the
U.S. prevalence of preexisting diabetes during pregnancy rose from 0.7% to 0.9% (CDC, 2018).
In 2009, roughly 1%-2% of pregnant women diagnosed with either preexisting diabetes or
complicated gestational diabetes required antihyperglycemics to control blood glucose (CDC,
2013, Law, et al., 2015, Sung, et al., 2012). These statistics are important to note because the
increased prevalence represents an increase in insulin resistance during pregnancy for these
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women, requiring increasing doses of antihyperglycemics to control diabetes during pregnancy,
while at the same time increasing their chances of episodic hypoglycemia.
During the Consensus Conference of the American Association of Clinical
Endocrinologists and American College of Endocrinology, leading experts in the field
determined CGM is likely to provide benefits for women with diabetes who are planning
pregnancy, as well as women with gestational diabetes (Fonseca, et. al., 2016). Further,
consensus participants unanimously agreed that patients who are prescribed antihyperglycemics
may also benefit, but barriers to the technology exist. CGM technology allows clinicians to
recognize fluctuations in blood glucose values, but this requires education and training.
For women with preexisting diabetes, blood glucose management in pregnancy begins at
the first prenatal visit. For some women, gestational diabetes is diagnosed later in the pregnancy
due to hormonal changes that occur within the placenta (Ngala, et al. 2017). Lifestyle
management, medical nutrition therapy, physical activity, stress, and sleep hygiene should be
part of the healthcare maintenance discussion for the pregnant woman with diabetes (ADA,
2020). Diabetes education begins with setting clear goals for maintaining optimal blood glucose
levels during pregnancy, clearly stating the maternal and fetal risks of hypo- and hyperglycemia,
discussing lifetime risks associated with diabetes during pregnancy, expected pregnancy
management and outcomes, and plans for delivery.
The recommendation for women with insulin dependent preexisting diabetes in
pregnancy is to check blood glucose at least seven times per day; for women with gestational
diabetes the recommendation is to check at least four times per day, while both populations
should be periodically counseled to achieve regular daily physical activity for 30-60 minutes, and
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to consume the nutritional accepted daily recommended intake (DRI) for pregnancy (ADA,
2020). Table 2 illustrates the ADA recommended guidelines during pregnancy.
Diabetes During Pregnancy Practice Guidelines
The American Diabetes Association publishes the Annual Practice Guideline for
clinicians to use to enhance care for pregnant women with diabetes. Table 2 demonstrates the
HbA1c and blood glucose targets recommended for pregnancy (ADA, 2020).The ADA
recommends fasting and postprandial glucose monitoring during pregnancy, and that some
women with preexisting diabetes or complicated gestational diabetes also test preprandial blood
glucose, although there is no set target goal found. For women prescribed antihyperglycemics
with multiple daily injections (MDI) or insulin pump infusion, the ADA recommends
preprandial glucose monitoring and one-hour postprandial glucose monitoring for premeal rapidacting insulin adjustment. CGM use among women with chronic diabetes during pregnancy, in
addition to standard care, demonstrate a mild improvement of HbA1c without an increase in
hypoglycemia. The Medtronic Guardian and the Dexcom G6 are the two CGM devices that have
received FDA approval for use during pregnancy. The Medtronic Guardian CGM uses the
CareLink software for data upload, download, and interpretation. See Figure 1 for the Dexcom
Clarity CGM software and Figure 2 for the Medtronic CareLink CGM software used for this
review. See Table 3 for the continuous glucose monitoring device comparison.
The American Diabetes Association (2020) recommends continuous glucose monitoring
devices in conjunction with insulin therapy for adults with type 1 and type 2 diabetes. CGM
therapy is effective in lowering A1c levels, reducing hypo- and hyperglycemia, and is deemed
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safe for those with hypoglycemia unawareness. Further, CGM use improves A1c levels, time in
range, and neonatal outcomes in pregnant women (ADA, 2020).
Problem Description
The implementation site was a subspecialty high risk obstetrical unit within a major
Northern California healthcare maintenance organization. The unit provides care to high risk
obstetrical patients referred by obstetrical providers and perinatologists throughout the region.
The unit operates at an average daily census of nearly 2000 patients assigned to a core of eight
registered nurse on dayshift and on evening shift to manage pregnancy complications such as
preterm birth, hypertension, and diabetes. The number of women referred to the unit for
management of diabetes during pregnancy has increased over time. In fact, the rate of women
pregnant with pregestational diabetes during pregnancy increased 37%, while women diagnosed
with gestational diabetes increased 56% from 2000-2010 (CDC, 2013). The registered nurses are
assigned a daily list of patients to call for telehealth appointments. These appointments typically
take 15 minutes to gather blood glucose data, review antihyperglycemic regimen, synthesize
information and data, and develop a treatment plan.
The unit operates 16 hours per day, seven days a week, and is open during all holidays.
Each of the eight registered nurses typically have 20-25 patients to call during the shift. Patients
referred to the unit were assigned a weekly telephone appointment. If a patient did answer the
call during the appointment time, the registered nurse left a message, and rescheduled the patient
within the shift when the patient called back. Women pregnant with chronic diabetes were
referred when viability was confirmed by observed cardiac activity and when the fetal pole
measured 7 mm on a transvaginal ultrasound corresponding with a gestational age of 6.0-6.5
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weeks (Gupta & Roman, 2019). From the first trimester, women spent an average of 28-36
weeks enrolled in the program. Women diagnosed with gestational diabetes were enrolled
between 24-28 weeks gestation and spent between 12-16 weeks on the program.
The blood glucose status of women referred to the unit range from controlled, somewhat
controlled, to uncontrolled. Most were currently using insulin, Glyburide, or minimal Metformin
dosages to control their blood glucose at the time of the referral to the unit. Once enrolled in the
program, the registered nurse educated the patient on diet, exercise, and lifestyle changes to
better control their blood glucose. After one to two weeks on service, the registered nurse made a
recommendation to the provider to optimize blood glucose control. The provider determined the
treatment plan, scheduled a one-on-one teaching appointment with a clinical registered nurse,
then sent a new medication order to the unit. The registered nurse subsequently and periodically
titrated the antihyperglycemic medication based on a protocol that was approved by the
leadership of the implementation unit.
Some women with chronic diabetes or complicated gestational diabetes were referred to
the unit with continuous glucose monitoring devices already in use. Prior to the pilot, the
registered nurse sent blood glucose reports to the primary care obstetrical provider or to the
perinatologist to make insulin adjustments rather than interpreting the data and adjusting the
insulin dosage at the point of care. This practice delayed patient care, limited registered nurses
from working at the top of their licenses and did not uphold the scope of practice outlined by the
American Association of Diabetes Educators (2017). The AADE scope of standards guide
diabetes educators’ practice, which include registered nurses as members of the diabetes care
team. Fonseca, et. al., (2016) recommends continuous glucose monitoring (CGM) training be
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made widely available to clinicians such as nurses and nurse practitioners, without formal
certification, as this adds barriers to CGM usage and isn’t necessary. Fonseca, et. al., (2016) also
suggests clinician training be expanded to all clinicians who care for patients with diabetes. This
pilot demonstrated CGM capabilities in a telehealth nursing unit, expedited patient care, and
allowed the primary care provider to commit time to acute patients who needed to be seen in
clinic. Prior to the pilot, no established standardization for utilizing CGM during pregnancy
existed for nursing staff. CGM and diabetes management education ensured registered nurses in
a telephonic nursing unit were prepared and competent making insulin dosage titration based on
the CGM Time in Range report. Per discussion with the leadership of the implementation unit, a
nurse practitioner-developed protocol for insulin adjustment was used for this project. See
Appendix K and Table 1 for the insulin titration protocol.
Available Knowledge
PICOT
Would nurses providing care to pregnant insulin-dependent women using CGM device
technology, compared to pregnant insulin-dependent women receiving standard care,
demonstrate increased confidence and competence when patients have a 50% decrease of
hypoglycemic episodes within three weeks of starting the program? To answer the question
about the reliability and accuracy of the continuous glucose monitoring time in range report used
by registered nurses as a clinical decision-making aid, compared to the standard care provided to
pregnant women with diabetes, a broad search of CINAHL Complete, Joanna Briggs Institute of
EBP (first search and PubMed), and Scopus electronic databases using the search terms
“diabetes, pregnancy, continuous glucose monitoring, nurse, training, education, and nurse
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practitioner” yielded 113 articles. Subsequently, 59 filtered free full-text, abstract, clinical trial,
random controlled trial, and systematic reviews published between 2010 to 2020 were accepted.
After further review, the remaining 16 articles used were limited to the English language; articles
that did not contain continuous glucose monitoring and pregnancy in the title, and articles
without an abstract were removed. Exclusion criteria of CGM devices other than Dexcom G6 or
Medtronic Guardian were applied because other devices used in the United Kingdom are not
approved for use in the United States by the Federal Drug Administration. The common themes
found in the reviewed articles were CGM therapeutic decision-making, CGM time in range
report provides clear goals, CGM use lowers HbA1c levels, CGM use reduces diabetes-related
complications, CGM education and training for nurses, and the role of the nurse practitioner.
Appendix A details the review of evidence grid.
CGM Guides Therapeutic Decision-Making
CGM is a safe and effective method to guide therapeutic decision-making for pregnant
women with diabetes when placed on the upper arm. Reliable CGM results correlate with the
self-monitoring blood glucose (SMBG) results, often detecting postprandial hyperglycemia, and
nocturnal hypoglycemia better than SMBG testing alone. The Time In Range (TIR) report has
been validated by multiple CGM clinical trials as a valuable tool for clinical decision-making
about insulin adjustments and has been proven to predict blood glucose trends so that changes
can be made in a timely manner (Castorino, Polsky, O'Malley, Levister , Nelson, Farfan,
Brackett, Puhr,& Levy, 2020; Gabbay, et al, 2020; Mazze, Yogev, & Langer 2012; Polsky &
Garcetti, 2017). The accepted glycemic variability range is 70 mg/dl to 180 mg/dl (ADA, 2020).
CGM accuracy and pattern reliability is not different than that of non-pregnant participants with
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diabetes. The Polsky & Garcetti (2017) study reported more values in the target range and
provided more blood sugar values than women not using a CGM. The accuracy of the Dexcom
G6 CGM to that of fingerstick blood glucose results (Castorino, et al., 2020) demonstrated CGM
accuracy of 92.5% when compared to that of non-pregnant Dexcom G6 CGM users who placed
the CGM on the upper arm. The study found the results of the Dexcom G6 CGM to be less
accurate when placed on the abdomen, or buttocks of pregnant women with diabetes. These
studies demonstrate that women with diabetes benefit from CGM device placement on the upper
arm, which results in more accurate data for providers to base clinical decisions.
CGM Time in Range Report Provides Clear Goals
Time in range (TIR) is the optimal blood glucose level achieved without inducing signs
and symptoms of hypoglycemia and has been correlated with less complications of diabetes.
However, if patients are to be counseled to maintain blood glucose in the optimal range,
registered nurses need to be trained to assess CGM data to make insulin adjustments. Eight
articles offered similar definitions and rationales for selecting TIR as a valuable tool for clinical
decision-making (Battelino, et al., 2019; Brown et al., 2019; Feig, et al., 2017; Gabbay et al.,
2020; Mazze, et al., 2012; Polsky & Garcetti, 2017;Vigersky & McMahon, 2019; Zaharieva, et
al., 2020). The International Consensus in TIR advocates for the use of TIR reporting as a
standardization for report glucose control and highlight the need to train clinicians and patients
on how to access, interpret, and use CGM tools to answer questions about glycemic control and
outcomes (Gabbay et al., 2020). According to researchers, participants who showed a high TIR
percentage indicated optimal glucose control and longer periods in the target range (Gabbay et
al., 2020). Similarly, reviewed studies support the conclusion that CGM provides complex data
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requiring analysis by trained clinicians. The TIR report is the most widely accepted CGM
download, most accurately measures blood glucose, and is relatively easy to interpret by trained
clinicians. As a blood glucose monitoring resource, the TIR is a valuable tool used to identify
nocturnal hypoglycemia when the patient displays nocturnal hypoglycemia unawareness (Brown
et al., 2019).
CGM Use Lowers HbA1c Levels
CGM use is associated with lowered HbA1c levels within 3 months of intensive diabetes
management or at the end of the pregnancy. The findings of the Advanced Technologies &
Treatment for Diabetes Congress were commissioned to develop clinical CGM targets to be used
by clinicians and others in interpreting reported CGM data (Battelino, et al., 2019). This study
reported 31% of CGM users with lower HbA1c levels after 4-6 weeks of monitoring, and
significantly lower HbA1c at 36 weeks gestation (Battelino, et al., 2019). The commission
recommended 3 core metrics specifically targeting CGM use during pregnancy. The 3 metrics
were identified as 1) percentage of blood glucose readings and time per day in the target range,
2) time below the target range, and 3) time above the target range. The commissioned experts
mutually agreed upon target percentages of TIR as the benchmark for making insulin
adjustments for diabetes in pregnant patients. Evidence supporting the use of the TIR report
show there is a strong relationship between percentage TIR and HbA1c when CGM results are
compared to SMBG results (Vigersky & McMahon, 2019). In relation to the HbA1c levels of
1,137 participants with type 1 or type 2 diabetes, researchers successfully demonstrated TIR
without episodes of hypoglycemia was achieved by use of CGM during pregnancy and was
verified by HbA1c test- the gold standard of glycemic control. The Vigersky and McMahon
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(2019) review discovered that for every 10% change in TIR, study participants achieved an
average 0.08% change in HbA1c. Likewise, Feig, et al. (2017) reviewed the risk of low
percentage TIR in the Diabetes Control and Complications Trial (DCCT) data. The DCCT is an
on-going, multicenter random controlled trial studying woman aged 18-44 who are <13 weeks 6
days pregnant with type 1 diabetes. This on-going clinical study spans across England, Canada,
Scotland, Spain, Italy, Ireland, and the U.S., and is designed to determine if intensive blood
glucose concentrations kept as close to normal result in early vascular complications.
CGM Use Reduces Risk of Diabetes-Related Complications
The difference in TIR between those that develop eye or kidney disease and others is
related to a decrease in TIR of approximately 2.5 hours per day in the acceptable range for those
using CGM. In the Feig, et al., (2017) study, pregnant CGM users spent more time in target at
68% than did the SBMG users who spent only 61% in the target range. This study concluded that
TIR is strongly associated with risk of microvascular complications and can be used as another
endpoint for clinical investigations, but further studies are needed. Another such example is the
Beck, et al., (2018) review that reanalyzed the dataset of the DCCT study to search associations
between TIR and development or progression of microalbuminuria or retinopathy. Using 545
subjects with type 1 diabetes out of 1,440 DCCT participants, researchers looked at capillary
measurements for one day every three months resulting in 32,528 quarterly data collections with
seven patient profiles complete for 24, 892 datasets, and found 19% met the criteria for
microvascular complications, while 9% met the criteria for microalbuminuria. Of the 1,440
participants, CGM users improved TIR by 80% and reduced hypoglycemic events by up to 40%.
The results of this study predict an increase in percent TIR decreases cumulative incidents of
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myocardial infarction, end-stage renal disease, severe vision loss, and amputations, lowering
overall healthcare costs by $6.7-$9.7 billion over 10 years.
CGM Reduces Incidence of Hypoglycemia
CGM users spend less time and have fewer incidents of hypoglycemia than SBMG users.
CGM use among women with diabetes during pregnancy reduces incidents of hypoglycemia, and
reduces the time spent with hypoglycemia symptoms. Hypoglycemia is defined as blood glucose
<70 mg/dl, while severe hypoglycemia is defined as <54 mg/dl. Both terms are universally
accepted (ADA, 2020). The goal of CGM is to identify episodes of hypoglycemia that otherwise
would not be captured by self-blood glucose monitoring of fingersticks at certain points in time.
CGM users are alerted 30-90 minutes of an impending hypoglycemic episode and can act before
feeling signs and symptoms. Symptoms of hypoglycemia include confusion, sleepiness,
tachycardia, diaphoresis, hunger, and irritability. CGM data can be accurately relied upon and
can be used as an effective means to record nocturnal glycemia to make individual adjustments.
Women with preexisting diabetes spend less time in hypoglycemia with continuous
glucose monitoring. In a study of randomized pregnant and nonpregnant adults, participants
showed a 48% reduction of nocturnal hypoglycemia, a 65% reduction of severe nocturnal
hypoglycemia, and a 40% and 54% reduction in daytime hypoglycemia and severe
hypoglycemia, respectively (Zaharieva, et al., 2020), but longer studies are needed to determine
the longer-term effects of CGM device use. For example, Polsky & Garcetti (2017) found that
participants who spent more time in the optimal glycemic range experienced less episodes of
hypoglycemia. In an alternate study, women with gestational diabetes or preexisting diabetes
wore a Medtronic Guardian CGM device to measure glucose exposure, glucose variability, and
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percent of time spent in hypoglycemia for at least 3 days on the abdomen area. All subjects were
treated with antihyperglycemics such as insulin, glyburide, or metformin during pregnancy. The
3-day CGM results were compared to 31 non-pregnant women with preexisting diabetes during
the same time period and resulted in less episodes of hypoglycemia (Mazze, et al., 2012).
CGM Education and Training for Nurses
Registered nurses are ideally positioned to provide education to people living with
diabetes, however, registered nurses without formal diabetes education lack the knowledge to
provide critical education to patients. Under direction and protocol of nurse practitioners,
registered nurses who work with patients with diabetes would benefit from CGM training,
intensive education and precepting on diabetes technology and management (Hollis, et al., 2014).
With CGM training and education, registered nurses can address knowledge gaps using best
practice guidelines and health promotion principles (Berget & Wyckoff, 2020). In the 51 U.S.
nursing jurisdictions, registered nurse scope of practice is broad and allows for development and
knowledge transfer. (Jones, 2015; Temple University, 2015). Nursing scope of practice allows
for dependent function, authorizes direct and indirect patient care services, including the
administration of medications and therapeutic agents necessary to implement a treatment ordered
by and within the scope of licensure of a physician (CA Board of Registered Nursing, 1995).
Nurses use skills that build on traditional models of collaborative care, promoting rapid uptake of
integrative technology, and support a broader context of the nursing process of assessment,
planning, implementation, and evaluation of the whole patient (Jones, 2015). Registered nurses
who specialize in diabetes management enhance opportunities for chronic-disease selfmanagement education and support. Nurses trained to titrate insulin dosages for women using
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CGM as adjunct therapy to multiple daily injections enhance diabetes control during pregnancy.
Utilizing the diabetes educator nurse leads to better outcomes and reductions in the risk for longterm complications (Jones, 2015).
CGM Certification
The Association of Diabetes Care and Education Specialists (ADCES) launched a new
CGM certificate program for those working in diabetes management to improve clinical
outcomes for people who use CGM technology (ADCES, 2019). The certification program is
voluntary and not required for practice in diabetes management. Access to the certificate
program is free for ADCES and American Association of Diabetes Educators (AADE) members.
Enrollees receive a certificate and earn up to 14.50 continuing education credits for completing
the online program, which can be applied toward registered nurse license renewal (ADCES,
2019).
CGM in Practice
Registered nurses care for patients using CGM in many different practice settings. The
US Food and Drug Administration has approved CGM for use in the school settings where over
50% of children with type 1 diabetes under the age of 18 use CGM technology. School nurses
rely on guidance from the American Diabetes Association (ADA, 2020) Safe at School education
and training tools on continuous glucose monitoring. The ADA offers courses designed to assist
school nurses with valuable information to reduce the burden that diabetes has on children in
school. The recommendations for use of continuous glucose monitors in the school setting offers
a summary of benefits on CGM use in the school setting.
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As an example, in other areas of practice, school nurses are part of the healthcare team
for students attending school with type 1 diabetes and who use CGM (Berget & Wyckoff, 2020).
With the increasing use of CGM among adolescents with type 1 diabetes, school nurses play a
vital part in caring for these students and must be comfortable providing care to support CGM
use during school hours. In addition to glycemic control management, school nurses must
receive education related to CGM devices, calibration requirements, and related reports and
trends. In collaboration with the primary care provider, the school nurse provides diabetes care
management to ensure optimal growth and development of the adolescent in her care. For
example, school nurses receive training to recognize arrow trends on CGM devices to predict a
rise or fall of a student’s glucose level, and utilization of the data-sharing capabilities to remotely
monitor blood glucose levels, minimizing frequent education interruptions while the student is in
class (ADA, 2020).
Nurses are in a unique position to educate interdisciplinary staff, patients and their
families by being an extension of the care patients receive in the clinic by the primary care
provider. In a separate study that measured nurses knowledge related to diabetes education and
training for nurses, Hollis, Glaister, & Lapsley (2014) found registered nurses received average
scores on basic diabetes management principles but scored significantly higher than average after
received additional CGM and diabetes education and training. In a follow-up questionnaire,
registered nurse qualitative data indicated increased confidence and competence in managing
people with diabetes (Hollis, et al., 2014).
Role of the Nurse Practitioner
Nurse practitioners play a critical role in diabetes care, routine monitoring and
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management of patients with diabetes. Nurse practitioners promote self-management, decision
support, and delivery system design. Patient education by nurses and nurse practitioners improve
the percentage of patients reaching metabolic targets. In a study measuring outcomes of patients
receiving diabetes education from a nurse practitioner-run clinic, one single visit with a diabetes
specialist nurse improved HgbA1c at 6 months with continued improvement to one year (Kruger,
2012). In a retrospective, cross sectional design study, patients with diabetes received specific
interventions according to a predetermined protocol. The clinic nurse performed the treatment
management by following the American Diabetes Association guidelines and followed patients
for 25 months. The clinical nurse gave personal counseling and educated patients about the
disease process and control, diabetes management targets, and follow up clinic visits during
telephone appointments. As a result of the nursing interventions, the patients’ blood glucose
showed a marked improvement (Ginzberg, et al., 2017).
Rationale
The Change Theory of Nursing is the basis of this paper’s theoretical framework. The
nursing theory was developed by Kurt Lewin to explain the phenomenon of overcoming
resistance to change. The three major concepts of the Change Theory are driving forces,
restraining forces, and equilibrium. Driving forces are those that facilitate change, leading to the
desired results. The driving force shift a change in the equilibrium. Driving forces and restraining
forces push change in the opposite direction, leading to a hinderance of change and an
equilibrium that oppose change. Equilibrium can be altered by the changes that occur between
the driving and restraining forces (Kaminski, 2011).

19

The three stages of the nursing theory are unfreezing, change, and refreezing. Unfreezing
involves utilizing a method to encourage the release of the old way of getting things done that
are not productive. Many patterns in nursing can be improved by fostering an environment that
promotes group conformity. This is achieved by increasing the driving forces that oppose the
existing situation. Decreasing the restraining forces that contribute to disequilibrium and
combing the increasing driving forces with the decreasing restraining forces is the process of this
framework (Kaminski, 2011). The premise of Lewin’s Change Theory helps to explain the
phenomenon of registered nurses being reluctant to adjust insulin dosages for pregnant women
who use continuous glucose management devices as adjunctive therapy even though it is within
the scope of their practice, and the policy and procedure exists to help them carry out procedures
safely. CGM use in pregnancy effectively identifies low blood sugar so that insulin dosages can
be adjusted by registered nurses, thus expediting care, increasing patient safety, adequately
controlling blood glucose, eventually restoring the counterregulatory hormone response, and
improving patient awareness overtime (Tkacs, 2002). See Figure 3 for Lewin’s Theory of
Change.
Specific Aim
This project changed clinical practice by providing a clinical decision-making tool
for registered nurses, improved the blood glucose of pregnant women who use CGM
during pregnancy, provided the registered nurse with a provider-developed insulin
titration protocol that quickly identified blood glucose trends, such as hypo- and
hyperglycemia, eliminated the delay in care and improved the care that registered nurses
provided to this vulnerable population. As a result of improved clinical decision-making,
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the registered nurses felt empowered to take swift action to make insulin adjustments
using the new insulin titration protocol, thereby reducing the of rate of hypoglycemia for
pregnant women who use CGM during pregnancy by 50% in the first 3 weeks of the start
of the pilot. See Appendix K for the provider-developed insulin titration protocol.
Lewin’s Theory of Change
Lewin’s Theory of Change was the basis of the three-step process to effectively
implement the provider-developed protocol. The first step of unfreezing began with the
initial needs assessment conducted to identify the gap in patient care provided to pregnant
women who use CGM during pregnancy. The previous practice of forwarding collected
blood glucose data to the provider who then made insulin adjustment recommendations
delayed care and allowed for continued risks of hypo- or hyperglycemia events. The
second step of Lewin’s Theory of Change occurred during the education and training on
CGM technology use during pregnancy, Time in Range report interpretation, review of
the provider-developed insulin titration protocol, and professional CGM documentation
and communication with the primary provider. The final step of Lewin’s Change Theory
took place during refreezing at the point when the new CGM during pregnancy pilot was
implemented.
Methods
Context
Assessment of the CGM technology interest, current nursing knowledge gap of
CGM device technology and report interpretation was necessary to determine the level of
education needed to provide evidence-based care to this vulnerable population. To
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accomplish this goal, the nursing staff completed a knowledge-based assessment on CGM
clinical use and decision-making which was the basis for the nursing CGM education.
This initial assessment also determined the level of interest for the pilot project. Prior to
the CGM education, the registered nurses took a pretest to measure CGM competency,
while the post-test assessed the efficacy of the CGM training.
Intervention
The intervention was the development of continuous glucose monitoring education
modules based on best practices. The intervention was chosen by this DNP candidate to improve
the registered nursing staff’s skills regarding pregnant women with diabetes management using
continuous glucose monitoring. The goal of the education modules was to increase registered
nurse knowledge on how to manage blood glucose of pregnant women with diabetes who use
CGM device technology. Secondary goals of the education modules were to decrease episodes of
hypo- and hyperglycemia, to safely decrease HbA1c levels during pregnancy, and to increase the
number of referred patients utilizing CGM device technology. The education modules included
PowerPoint slides on CGM devices and report interpretation for clinical decision-making.
The education modules included case studies to guide clinical decision-making. The
modules also included evidence-based practice guidelines provided by the American Diabetes
Association, CGM education and training principles of the Association of Diabetes Care and
Education Specialists, CGM device manufacturer user guides, and a review of the new insulin
titration protocol. Pictures of CGM reports, trends, and blood glucose values were reviewed. The
PowerPoint slides were reviewed by the student nurse practitioner who has experience using
CGM devices and interpreting reports to make insulin dose changes. Institutional and
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departmental leadership reviewed the guidelines and parameters by which registered nurses
provided patient care. Registered nurses called patients weekly to review CGM Time in Range
(TIR) report, assess dietary intake and physical activity, and titrated insulin dosages based on
CGM Time in Range report interpretation using the new protocol. Management participated in
the review and development of guidelines and parameters based on the American Diabetes
Association clinical practice guidelines, Medtronic Guardian CGM and Dexcom G6 user
manuals by approval of institutional leadership. A team of registered nurses were recruited to
assist with CGM education and evaluation of the nursing staff. The project team used Microsoft
Teams to communicate progress on their individual contribution, needs, and requests to ensure
the project was completed within budget and on time. The project benefited all insulin-dependent
diabetes patients currently utilizing CGM device technology during pregnancy in the Northern
California healthcare maintenance organization region.
Continuous Glucose Monitoring Training
Registered nurses completed four online training modules on CGM device technology
and reporting software interpretation. Module one reviewed the Medtronic Guardian CGM
device and CareLink software basics, the Dexcom G6 CGM device and Clarity software basics,
CGM terminology, blood glucose report selection, and blood glucose report interpretation.
Module two discussed CGM documentation and communication of reporting data to providers
and methods for sharing data with interdisciplinary team members. Module three introduced the
new insulin titration protocol for patient’s using multiple daily injections. Module four provided
the registered nurses the opportunity to participate in a case study to correctly identify pertinent
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blood glucose data and apply the new CGM protocol to titrate insulin for pregnant women with
diabetes. See Appendix J for an explanation of the online training modules.
Study of the Intervention
GAP Analysis
After reviewing local resources, infrastructure, and processes, there was no program
available to provide care for insulin-dependent women using CGM during pregnancy. The
current practice of deferring insulin titration for pregnant women using CGM device technology
during pregnancy to the perinatologist delayed patient care and limited the registered nurse from
working at the top of their licenses. A second gap was identified that involved the variances in
insulin-dependent diabetes education of the nursing and interdisciplinary staff. For example,
when providing standard care to pregnant insulin-dependent women, some nurses titrated insulin
up to the maximum dose allowed within the protocol (20%), but some nurses were more
conservative and titrated insulin near the minimum dose (10%). This flexibility within the
existing protocol was not evidence-based, nor did it fit the diabetes management protocol for
provision of safe, high-quality diabetes care across the continuum of care, and could not be the
basis of the CGM device and diabetes management project. The conservative approach to
insulin-based care was based on fear of the unknown in terms of risks associated with
hypoglycemia and a lack of confidence on behalf of the nurse. (See Appendix B).
Stakeholders
The stakeholders were management, leadership, physicians, advanced practice clinicians,
and registered nurses. Management was a major stakeholder with significant influence, high
impact and importance, with the ability to block the project, requiring immense engagement to
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keep the project on track. Institutional leadership was a stakeholder of high influence, high
impact and importance, with the ability to contribute or block the project, and took minimal
engagement to keep the project on track. Physicians were stakeholders with some influence, low
impact and influence, but of high importance, with some contribution, with no ability to block
the project, and took little engagement to keep the project on schedule. Lastly, registered nurses
were key stakeholders of high impact, importance, and influence who made high contributions,
with no ability to block the project, requiring a significant amount of engagement to keep the
project on schedule. (See Appendix C).
SWOT Analysis
The SWOT analysis project management tool identified areas of improvement, provided
information to the project manager, ensured the project was completed on time, within budget,
and helped to alleviate risks associated with tasks (Lim, 2012). The SWOT analysis for the CGM
and Diabetes Management project identified several strengths, weaknesses, opportunities, and
threats, which are described below.
Strengths
The strengths associated with the CGM and Diabetes Management project included
increased confidence and competence among the registered nurses, expediency of care provided
to patients using CGM technology, increased patient safety by decreasing in the number
hypoglycemic episodes which was a provision of the 16-hour nursing support system, and the
utilization of SMART goals in the project management of the assigned tasks. Expediency of care
was identified as a strength of the CGM and Diabetes Management project because it minimized

25

risk by offering a seamless delivery of care through integration, coordination, and utilized the
interdisciplinary team approach in project management.
Healthy People 2020 identified patient safety and quality as a leading health indicator and
provided an evidence-based resource summary on improving the outcome of pregnancy and
enhanced perinatal health through quality, safety and performance initiatives
(healthypeople.gov). This resource provided the evidence necessary for offering 16-hour nursing
support to vulnerable populations. SMART goals utilization was identified as a strength because
when referenced in relationship to project management, the ability to successfully achieve goals
was enhanced.
Weaknesses
The weaknesses were identified as the variability of CGM and diabetes management and
insulin titration by the nurses, patient compliance with weekly phone calls, lack of an increase in
patient census, and the limited supporting evidence in the literature because a project proposal of
this type was unprecedented. Patients were less likely to adhere to nursing advice when
historically, care was provided by perinatologists or diabetes endocrinologists. Patients typically
did not answer the registered nurse’s call when trust was not established or when patient’s felt
the service was not beneficial because the nurse was unable to titrate insulin dosages based on
the CGM reports. Expanding the diabetes management during pregnancy program to CGM users
was hypothesized to inversely increase the patient census when the project was supported by
institutional leadership; however, this did not occur. Lastly, the lack of supporting evidence in
the literature due to the unique nature of this project was a weakness when information was
presented to stakeholders.
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Opportunities
The opportunities were reduced hypo-and hyperglycemic episodes, increased patient
safety, enhanced clinical decision-making, increased confidence and clinical competence among
the registered nurses, garnered institutional leadership and provider support, the utilization of
interdisciplinary teamwork, program recognition and modeling, a service provided to a
vulnerable population, and the utilization of evidence-based standards. The implication for
change varied and served many purposes. Implementation of this project eased congestion in the
clinic and garnered perinatologists’ support. As this project provided a valuable service to a
vulnerable population by utilizing evidence-based standards and provided recognition to the
institution as a model for other healthcare systems to follow in the future.
Threats
The perceived threats to the CGM and Diabetes Management project included resistance
from the registered nurses, lack of sponsor support, provider resistance, and pushback from
competing subspecialty units. The threat that was most anticipated was resistance from registered
nurses. This threat was highly expected because registered nurses expressed concern with the
increased work involved with previous projects. Registered nurses were resistance to change and
voiced opposition to the increased responsibilities and workload as they learned a new practice
care delivery system. However, with transparency, clear communication, and adequate training,
this threat was overcome.
Provider resistance was expected from providers who lacked knowledge of the unit’s
expertise in perinatal glucose monitoring, lack of project objectives, and lack of understanding
the potential benefits to the population being served. Pushback from competing subspecialty
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clinics were anticipated because they perceived the project was taking responsibilities and
patients away from the services they provided. One such subspecialty clinic was the Diabetes
Clinic, which operates at major hospital satellites in the perinatology clinics throughout the
healthcare institution’s Northern California region. These subspecialty clinics operate
independently of each other and often did not refer their most complicated pregnant insulindependent patients using CGM unless care involved only routing collected blood glucose data
from the patient to the Diabetes Clinic.
However, with education on the benefits of the project, which closed the CGM and
diabetes management gap, the perinatologists in the Diabetes Clinics realized the CGM and
Diabetes Management During Pregnancy project provided quality, safe, evidence-based care.
Lastly, the lack of sponsor support threat was evident by resistance from the registered nurses
and providers, and pushback from competing subspecialty clinic perinatologists that eventually
were overcome. (See Appendix D).
Work Breakdown Structure
The Work Breakdown Structure (WBS) provided a breakdown of all the steps of the
project. The Continuous Glucose Monitoring and Diabetes Management During Pregnancy
program consisted of five phases. Phase One was the initiation phase where meetings with
leadership and management took place to discuss the project proposal. Phase Two involved the
planning phase of the project. The project manager worked closely with management to select
key team members and oversaw the development of the kick-off meeting. Phase Three occurred
in conjunction with the first step of Lewin’s Theory of Change of unfreezing, and involved the
planning and development of the policies, procedures, and the provider-developed insulin
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titration protocol of the project with institutional leadership and management using ADA clinical
practice guidelines, and CGM device user manuals. Phase Four, also step two of Lewin’s Theory
of Change, initiated the registered nurse education and training on CGM technology and report
interpretation. Phase 5 and step three of Lewin’s Theory of Change began with the
implementation of the project pilot, analysis, discovery, acceptance of results and ultimately
archiving of data. (See Appendix E).
Budget
The budget was based on the salaries of the registered nurse’s hourly wage. The
education meetings took place during Microsoft Team meetings prescheduled with the
assistance of management and the project manager. Microsoft Teams provided a platform
to meet regularly, within strict timeframes, with limited costs, and by continued
adherence to the social distancing policy currently in place. The average hourly wage for
a registered nurse was $77.00 per hour. There were 36 registered nurses who were invited
to participate in the education meetings. The total for all training sessions was budgeted
at $2772.00, however due to the COVID-19 temporary work from home policy change,
the nurses completed the CGM education and training modules at home independently.
This ultimately cost the unit zero dollars. (See Appendix F for the estimated budget prior
to the COVID-19 temporary work from home policy enactment).
Communication Plan/Matrix
Microsoft Teams was used as the communication board method of communication
between the project manager, leadership, and team members. The supervising faculty
chair was provided updates from the communication board as required and stated on the
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DNP Statement of Non-Research Determination Form (see Appendix G). The
communication board was customized for each team member, improving communication
board utilization and reporting. The communication board ensured that each team
member knew their responsibility, held each team member accountable, and provided
transparency for leadership. Leadership was well informed of the scope of the project, the
timeframe for completion of the project, accurate costs of the project, met stakeholder’s
expectation by displaying push back from the project manager. Transparency provide d
accuracy and led to improved decision-making. Communication board reporting was an
important concept of the project management. The benefit of current, accurate, and
relevant communication board reporting required that updates were completed daily
because it held team members accountable for the scope, time, and costs of the project.
One of the benefits of utilizing communication board reporting was the customization to
each individual team member’s needs. Therefore, team members only need ed to access
areas of the communication board that related to their individual contribution, as all team
members were well informed of progress during weekly Microsoft Team meetings. To
mitigate planning and decision-making, weekly Microsoft Teams meetings were held to
bring all team members together for discussions related to data collection and fulfilled
request for feedback from stakeholder and team members. Weekly Microsoft Team
meetings provided opportunities to ask important questions and overcome obstacles. (See
Appendix H for the communication board method).
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Measures
Smart Goals
To measure outcome goals, this project used the SMART goal template. The
specific goal of educating the training the registered nurses for required analyzing their
level of readiness and education. The resources to provide the education were created.
Each registered nurse was equipped with a computer, Microsoft Teams acces s to facilitate
communication, and management support for the pilot.
The primary measurement tool identified for this project was the qualitative data
retrieved and analyzed from the Qualtrics pre- and post-surveys given to the registered
nurses upon completion of the four modules. The secondary outcome measures were the
HgbA1c <7.0 percent and 50% reduction of hypoglycemic episodes of patients referred to
the program. The specified goal of safely improving patient glycemia and expanding
diabetes management to include CGM knowledge would empower the registered nurses
to care for this population, and accurately adjust insulin dosages using the CGM device
reports along with the glucometer blood glucose readings.
The goal to improve glycemic control during pregnancy using CGM device
technology while also reducing episodes of hypoglycemia was attainable. After
assembling a team to work together to identify potential pilot participants, patients
eventually were referred to the unit and assigned to a registered nurse for weekly
telephone appointments. This contact required no special equipment of expenditures for
the registered nurse or the patient.
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Relevancy of the stated goals was determined because the strategy for e -learning
fit within the current temporary work from home policy as a result of the COVID-19
pandemic. The defined goals are time based because the training and education the
registered nurses received now allows them to take immediate action when identifying
abnormal glucose values on the CGM report.
Each nurse who agreed to participate in the pilot understood the end date for
achieving the goals and understood the time and structure of the pilot. Once Northern
California HMO members were referred to the implementation unit with a confirmed
IUP, the registered nurses applied the learned CGM technology, diabetes during
pregnancy support, and medication titration protocol via weekly telephone appointments.
It is of my opinion, and the reason for the pilot project, that the implementation unit
could do more to provide care to insulin-dependent women who use CGM device
technology. This can be accomplished by interpreting Time in Range reports and titrating
insulin dosages when hypoglycemic episodes are identified. It is possible to reduce
HgbA1c levels safely during pregnancy by using the ADA recommended guidelines.
Prior to enrollment, members had a baseline HbA1c drawn, and subsequent levels drawn
each month until delivery or at the end of the pilot, whichever came first. The timeline
for the pilot project was for a maximum of twelve weeks. These goals were realistic and
feasible because the implementation unit had the staff, time, and support of leadership at
project implementation.
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Analysis
Qualtrics was used to provide gap analysis, and pre- and post-surveys. The
registered nurses were given a gap analysis survey to determine their CGM device
technology and report interpretation educational needs. Information gathered from the
Qualtrics were used as the basis for the continuous glucose monitoring blood glucose and
CGM report interpretation training modules. After CGM training, registered nurses took a
posttest to measure hypo- and hyperglycemia trending and recognition, appropriate blood
glucose report selection and data interpretation. Efficacy of continuous glucose
monitoring training, and the knowledge gap assessment was measured by comparing the
pretest and posttest results. Based on the outcome answers, education targeted the needs
of the registered nurses and was be beneficial during the pilot. Lastly, the post-test
measured the level of understanding of the education provided. Any information that was
not understood or required remediation was evident on the post-test survey. See
Appendix I for the Qualtrics pre-test survey.
Ethical Considerations
While the goal of this project proposal was to provide information and data
supporting the need to provide quality care to a vulnerable populatio n, leadership based
their decision-making on qualitative and quantitative analytics. The primary objective
was to increase the knowledge of the registered nurses in CGM device technology.
Evidence supports the on-going education of clinicians who manage the blood glucose of
patients using CGM device technology. IRB consideration was not necessary for this
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project as it was a quality improvement project that changed practice to provide better
care for patients. See Appendix G for the DNP SOD form.
In the Jesuit tradition at USF, we are taught just as the Lord taught Cain in Genesis 4:9
about the role of honesty and respect in our lives. When the Lord asked Cain where Able was,
Cain responded “Am I my brother’s keeper?” As a nurse, the answer is a resounding “Yes!”. The
American Nurses Association Code of Ethics encompasses three provisions that specifically
apply to this project: Provision 3.4 explains professional competence in nursing practice,
Provision 5.5 further encourages maintenance of competence and professional growth, and last,
Provision 7.2, which details contributions through developing, maintaining, and implementing
professional practice standards in the nursing profession. This project accomplishes and adheres
to all the aforementioned provisions and in the spirit of the Jesuit teachings at the University of
San Francisco’s School of Nursing and Health Professions.
Results
CGM and Diabetes Management During Pregnancy Pre-Education Survey
The CGM and diabetes management during pregnancy pre- and post-education and
training surveys were created for this project using Qualtrics. The pre-education and training
survey consisted of six questions and was sent to 30 registered nurses in the unit to determine the
level of interest for the pilot project. Of the 30 registered nurses, nine completed the survey
before the start of the pilot, nine didn’t respond, five declined to take the survey but verbalized
their interest in the CGM and education and training modules, four retired before completing the
survey, one retired after submitting the survey, one transferred to a different inpatient unit, and
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one went on medical leave of absence and did not complete the pre-education and training
survey. See Appendix M for the post-education and training survey.
CGM Education and Training Modules
Four modules were created to educate the registered nurses on CGM technology and to
training them on the NP-developed insulin titration protocol. Module One introduced CGM
devices used during pregnancy, recognition of two CGM devices, instructed on accessing CGM
software websites for viewing CGM data and reports, understanding basic CGM terminology,
including how CGM works, appropriate blood glucose report selection, and interpret blood
glucose reports to aid in clinical decision-making about insulin titration.
Module Two established the agreed upon professional documentation and data sharing
requirements for CGM and diabetes management. The professional documentation standards
were agreed upon during the Advanced Technologies & Treatment for Diabetes Congress
commissioned by leading experts in 2016 and affirmed in 2019 (Battelino, et al., 2019). The
module explained professional CGM documentation, application of the knowledge of
professional CGM standards to documentation in the HER, developing simplistic weekly
goalsetting for patients, and communicating appropriate recommendations to providers.
Module Three introduced the NP-developed insulin titration protocol and a new practice and
procedure for the pilot project. The NP-developed protocol is based on prior ACOG and ADA
guidelines used to develop the existing insulin titration protocol approved for patients referred to
the Home Glucose Monitoring Program. This protocol is referred exclusively for pregnant
women with diabetes who are referred with CGM during pregnancy, and who control their blood
glucose using multiple daily injections of rapid-acting insulin such as Lispro or Humalog, fast-
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acting insulin such as Regular insulin, and intermediate-acting insulin such as Humulin-N, or
NPH. The protocol was developed to assist providers who refer patients using CGM with the
expectation that registered nurses will titrate insulin based on daily fingersticks for fasting blood
glucose, and 1-hour postprandial for breakfast, lunch, and dinner. However, CGM allows the
registered nurse to view blood glucose that is collected every 5 minutes, for up to 255 blood
glucose values in 24 hours, viewable on the CGM software website. The NP-developed protocol
uses the patient’s BMI to titrate insulin dosages based on increases or decreases of 10-20% of the
previous insulin dose.
In Module Four, registered nurses identified CGM devices, accessed the correct CGM
software website, selected the appropriate blood glucose report, interpreted blood glucose reports
in comparison to the SMBG, discussed lifestyle, dietary, and medication management causes for
hypo- or hyperglycemia, set simplistic weekly blood glucose goals, transcribed professional
documentation for sharing with providers. Module Four discusses continuous glucose monitoring
and diabetes management during pregnancy by practicing CGM management in a case study
format. See Appendix J for the four education and training module topics. See Appendix L for
the Module PowerPoint slides.
CGM and Diabetes Management During Pregnancy Post-Education Survey
Of the remaining staff, 23 registered nurses were invited to participate in the four
education modules and complete the post-education survey. At the time of this paper, 17.4% of
the registered nurses completed the post-education survey although 52.2% of respondents
completed all four modules and began using the new protocol in practice during the pilot. Survey
results indicated 100% felt the CGM module education level was appropriate for their learning,
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100% reported the graphics and module transcripts enhanced their learning, 50% reported their
knowledge of CGM and diabetes management during pregnancy increased since completing the
CGM education and training modules, 100% felt confident providing care to patients using
multiple daily injections and CGM as adjunctive therapy after completing the CGM modules,
and 100% reported a clear understanding of the NP-developed CGM insulin titration protocol
after completing the CGM education and training modules. See Figure 4 and Figure 5 for
statistical data.
CGM and Diabetes Management During Pregnancy Pilot
Pilot participants were selected based on referral criteria from the primary obstetrical
provider. Qualified participants were selected starting in June 2020 due to the limited number of
CGM users during pregnancy in the region. At the time of enrollment, the participants ranged
from eight weeks to 13 weeks gestation and were enrolled for an average of 16 to 25 weeks.
Three patients were induced at 38 weeks gestational age in accordance with ACOG guidelines.
The referral criteria are confirmed pregnancy viability, enrollment HgbA1c, glucometer and
supplies, dietary consultation with a registered dietician, smartphone or CGM receiver, CGM
device, basal insulin and preprandial insulin prescription with refills available. The pilot
participants were asked to give the login information for the CGM device platform for weekly
review during the telephone appointments. The patients were scheduled for weekly telephone
appointments with the registered nurses to review multiple daily injection (MDI) blood glucose
values to compare to the CGM sensor glucose values. If the patient did not answer the phone for
their scheduled telephone appointment, the primary obstetrical provider was notified of the
patient’s non-engagement and the patient was expected to call back upon receipt of any
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voicemail or secure message sent by the registered nurse. After three weeks of non-engagement,
the patients would then be discharged from the pilot and program.
In 2020, a total of 10 patients using a CGM device as conjunctive therapy with diabetes
management were referred to the program. Nine of the 10 patients were pregnant and were
enrolled in the project pilot. One patient was referred to the program but was not included in the
pilot project because she was not currently pregnant, although she was prescribed a CGM device
for use in the preconception counseling program. The registered nurses assigned to her
management plan participated in the CGM education and training modules and reported positive
responses on the post-education and training surveys.
Overall, three patients enrolled in the pilot completed the program and delivered healthy
infants, three are still pregnant and enrolled in the program, and three were discharged from the
program due to non-engagement. Non-engagement is defined as three consecutive weeks without
contact with the registered nurses and is a departmental policy requirement. Once discharged
from the pilot and the program, the patients were referred to the primary obstetrical provider for
continued coordination of care. These patients will be offered re-enrollment in the program when
they are ready to be reinstated.
Nursing Interventions
The four options of nursing intervention were 1) none needed, 2) registered nurse
adjusted insulin using the NP-developed insulin titration protocol and routed to the obstetrical
provider for review, 3) registered nurse routed to obstetrical provider for insulin adjustment
recommendations based on patient concern, and 4) registered nurse adjusted insulin using the
NP-developed insulin titration protocol for a maximum of 20%, and routed to the obstetrical
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provider for additional adjustment greater than the protocol allows. See Appendix K and Table 1
for the NP-developed insulin titration protocol.
Starting Average Hemoglobin A1c
The highest starting HgbA1c was 9.8% while the lowest was 4.7%. As a departmental
policy, patients complete the HbgA1c lab test monthly. All participants successfully completed
this requirement as ordered. Of the patients who successfully continued the pilot for the duration
of their pregnancies, all showed improved HgbA1c except one. The average starting HgbA1c
was 7.23% while the average final HgbA1c was 5.83%. While a decrease in HgbA1c was
expected, as the literature supports, the speed at which the benefits of CGM during pregnancy
became evident was a surprise. The pilot demonstrated a decrease of 1.4 percentage points in
HgbA1c for these women. See Figure 6 for graphical data.
Hypoglycemia
Two of the nine participants had a history of regular hypoglycemic episodes prior to
enrollment. One of the two participants experienced severe hypoglycemia requiring
hospitalization prior to pregnancy, complicating diabetes management due to extreme
hypoglycemia unawareness and an increased risk of nocturnal hypoglycemia.
Two of the nine participants experienced daytime hypoglycemia during the first two
weeks enrolled in the pilot related to skipping the mid-morning snack and increased physical
activity. These episodes were captured on the CGM report and immediately corrected by the
registered nurse after decreasing the morning basal insulin. The intervention was based on the
NP-developed protocol, resulting in episodic hypoglycemia absence for the duration of the pilot.
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In total, all nine CGM and diabetes pilot participants reported zero episodes of
hypoglycemia for the duration of the pilot after receiving education from the registered nurses on
CGM report interpretation and after the CGM alarm settings were changed in accordance with
ACOG and ADA recommendations for CGM use during pregnancy. Hypoglycemia avoidance
was discussed at each weekly telephone appointment.
Secondary Outcome Measures
The secondary outcome measures were related to maternal and fetal wellbeing. Although
these two components of care were not intended as a primary measurement during the pilot,
literature identified the need for ongoing research to establish them as primary outcome
measures. As a result of close surveillance of blood glucose with MDI, glucometer blood
glucose, and CGM sensor glucose, maternal outcomes revealed two of the three pilot participants
who delivered did so vaginally. All three infants were delivered with a normal fetal weight of
less than 4,000 grams as recommended by ACOG, and none required neonatal intensive care unit
admission for hypoglycemia. One pilot participant delivered via cesarean section due to
complications of preeclampsia that was unrelated to the CGM and diabetes management during
pregnancy care received during the pilot.
Final Average Hemoglobin A1c
All but one patient showed a decrease in HgbA1c by the end of the pilot or at delivery.
The final average HgbA1c was 4.49% among the pilot participants. The HgbA1c improvement
score was calculated by subtracting the starting average HgbA1c from the final HgbA1c for a
total improvement score of 2.81 percentage points. The improvement score was achieved by
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successfully implementing the NP-developed insulin titration protocol without inducing signs or
symptoms of hypoglycemia. See Figure 4 for the hemoglobin A1c comparison.
Discussion
Summary
The specific aim of the pilot was to reduce the of rate of hypoglycemia for pregnant
women who use CGM during pregnancy by 50% in the first 3 weeks of the start of the
pilot. Further, the goal of reducing the HgbA1c level at the end of pregnancy or the end
of the pilot was also achieved, improving maternal and fetal outcomes as an unintended
secondary measure. Evidence is compelling and strong that registered nurses should be trained
to use CGM device technology. With training, registered nurses work within their scope of
practice to use CGM device technology along with a provider-developed protocol when caring
for this population. The evidence contributes to the advocacy that all pregnant women with
diabetes should have access to a CGM device to reduce the burden of diabetes on pregnancy, but
more studies are needed to determine long term benefits and neonatal and maternal outcomes.
Interpretation
As evidenced in the studies examined for this pilot, there were no established
standard of care utilizing CGM technology and preprandial blood glucose goals. The
ADA’s postprandial blood glucose recommendations, in conjunction with clinical CGM
targets developed by the Advanced Technologies & Treatment for Diabetes Congress
provide some evidence that CGM can improve BG control, limit blood glucose variab ility
by allowing early intervention, reduce episodes of hypo- and hyperglycemia, and is safe
when used during pregnancy.
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Although standardized procedures utilizing CGM are needed for nurses taking care of
pregnant women with diabetes, no such established standardization existed prior to the pilot. The
pilot evidence indicates that CGM can help achieve an adequate HgbA1c when used as adjunct
therapy with self-management blood glucose (SMBG) without increasing the risk of
hypoglycemia during pregnancy. CGM greatly reduces the burden of diabetes during pregnancy
by reducing the number of fingersticks required to accurately and safely titrate insulin. CGM is a
reliable method for making clinical decisions about insulin and glycemic goals. CGM use has not
been associated with adverse outcomes during pregnancy and reduces the lack of hypoglycemia
awareness by accurately predicting hypoglycemia by up to one hour before an occurrence.
CGM can accurately identify low blood glucose trends, can be used effectively in
conjunction with standard care during pregnancy to aid in the treatment of diabetes in pregnancy.
The reviewed articles share the common conclusion that CGM data accurately report blood
glucose values when compared to SMBG data. The literature recommends CGM as adjunct
therapy for identifying and correcting hypo- and hyperglycemia, found comparable
outcomes to women without diabetes during pregnancy, and used the same blood glucose
target goals of 70 mg/dl to 180 mg/dl as recommended by the American Diabetes
Association. The pilot adopted the literature evidence in the clinical decision-making tool that
was also part of the innovative protocol for insulin titration used by the registered nurses.
Several articles specifically advocated for registered nurses to be trained on report
interpretation of CGM devices, and highlighted barriers to expanded CGM use due in part to lack
of diabetes specialist education and training (Battolino, et al., 2019; Fonseca, et al., 2016; Hollis,
et al., 2014; Berget & Wyckoff, 2020). The strongest piece of evidence reviewed was the
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article discussing the Advanced Technologies & Treatment for Diabetes Congress that was
commissioned to develop clinical CGM targets (Battolino, et al., 2019). This article was used as
a basis for developing a protocol to guide clinical decision-making because it compared two of
the most common CGM devices, the Medtronic Guardian and the Dexcom G6 (see Table 3).
Researchers (Battolino, et al., 2019) suggested clinicians and patients be trained to accurately
interpreter the time in range report to make clinical decisions and insulin titration. The intent of
the panel was to provide clinicians with the metrics needed to obtain and interpret current blood
glucose levels and adjust therapy accordingly.
Limitations
The limitations of the project were the small sample size of the cohort, limited
participation of the registered nurses, the limited timeframe of the pilot, and non-engagement of
three of the nine pilot participants which led to discharge from the program. The cohort sample
size was small due to the lack of CGM during pregnancy users enrolled in the healthcare
maintenance organization. Some primary obstetrical providers prefer to manage the blood
glucose of their patients without referral to the program, while some patients prefer to be
managed in clinic weekly and chose to not use the telephone appointment capabilities of the
registered nurses, however, the specified statistics were not available for analysis in this project.
The pilot project discussion began with leadership in December 2019. The decision was
made to start screening patients during the recruitment process in June 2020 when the first CGM
during pregnancy users were referred to the program. The recruitment process began before the
pilot implementation since patient are typically referred very early in the pregnancy, and because
referral to the program historically is scarce.
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Considerable literature is limited of long term random controlled trials involving CGM
use during pregnancy and are on-going. For this reason, CGM education and training modules
and the NP-developed insulin titration protocol was created specifically for the pilot. As the ongoing studies progress, new information will be elicited. A major weakness of the studies
reviewed for the pilot was that none discuss maternal and fetal outcomes as an important theme
worthy of research. Among the articles, researchers (Polsky & Garcetti, 2017) determined more
studies are needed to conclude long term benefits and neonatal and maternal outcomes. The link
of nocturnal hyperglycemia to that of large for gestational age (LGA) neonates was attempted by
Battolino, et al. (2019) but the study authors failed to specifically correlate the data as such,
concluding with a need for more studies. Limiting the data by not conducting follow up studies
of this important dataset means clinicians will continue to work to decrease daytime
hyperglycemia without knowing if basal insulin should be titrated to decrease nocturnal
hyperglycemia, potentially preventing LGA neonates who require intensive care following birth.
Conclusions
The findings from the pilot project, while supported by the literature, indicate that the
interpretation of continuous blood glucose reports is an essential function of registered nurses
who provide care for pregnant women who use CGM with diabetes. However, to perform this
essential function during the pilot, registered nurses were provided a protocol to follow and
CGM education and training to interpret the critical CGM report data. A lack of CGM education
and training was a barrier that subsequently delayed care and had a negative impact on the
patient’s blood glucose control during pregnancy. As a result of the pilot program, pregnant
women using CGM devices as adjunctive therapy to MDI diabetes management experienced
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decreased episodic hypoglycemia, zero episodes of nocturnal hypoglycemia unawareness,
improved HgbA1c, and vaginal delivery of normal weight infants who did not require neonatal
intensive care unit stay.
The following recommendations are made for providing evidence-based care to pregnant
women who use CGM device technology during pregnancy. Nurse practitioners possess the
skills, education, training, and leadership experience to train registered nurses on CGM report
interpretation. CGM education and training should be made widely available by nurse
practitioners to all registered nurses who provide care for patients who use CGM devices.
Registered nurses should be allowed to perform independent and dependent functions when
using a nurse practitioner-developed protocol to provide care for pregnant women with diabetes
who use continuous glucose monitoring during pregnancy. Evidence supports educating and
training registered nurses on continuous glucose management device technology to improve
blood glucose and to aid in the clinical decision-making process.
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Appendix A
Review of Evidence Grid
Key: Johns Hopkins Nursing Evidence-Based Practice Research Evidence Appraisal Tool LOE: level of evidence (LoBiondo-Wood & Haber)

Category (Level Type)

Level I
■

Experimental study

■

Randomized controlled trial (RCT)

■

4

Overall
Quality
Rating
A: High
Quality

Synthesis of Findings
Evidence That Answers the EBP Question
1.

Systematic review of RCTs with or without metaanalysis

Explanatory mixed method design that includes
only a Level I quantitative study

■

Total
Number of
Sources/
Level

2.

3.

4.

CGM training should be made
widely available to clinicians such
as nurses and NPs, Formal
certification would add to more
barriers and isn’t necessary.
Clinician training should be
expanded.
Dexcom G6 CGM is a reliable
tool during pregnancy. Accuracy
of CGM results associated with
placement on upper arm. CGM
may be beneficial to women with
other types of DM. Limitation is
small sample size (32 pregnant
women 18-34 yrs old; 15 T1D
using MDI; 5 T1D using CSII; 3
T2D, 9 GDM), (Castorino, et. al.,
2020).
TIR streamlines data
interpretation and provides more
information than A1c alone and
facilitates safe and effective
therapeutic decision-making
within glycemic parameters. TIR
should be increased during
pregnancy as quickly as possible.
Clinician inexperience in data
interpretation plays a role in the
underutilization of CGM use
during pregnancy. (Battelino, et.
al., 2019).
This study analyzed data of 132
women on the impact of CGM on
maternal, fetal, and neonatal
outcomes by attempting to explain
the trimester-specific timeframe
contributing to LGA by
identifying BG variability. There
was no significant difference in
mean A1c levels among mothers
w/ LGA infants compared to those
w/o LGA infants; DM pregnancies
were clinically well controlled.
(Law, et. al., 2015).

51

Level II
■

3

Quasi-experimental studies

Systematic review of a combination of RCTs and
quasi-experimental studies, or quasiexperimental studies only, with or without metaanalysis

A: High
Quality

1.

■

2.

Explanatory mixed method design that includes
only a Level II quantitative study

■

3.

Level III
■

3

1.

Nonexperimental study

Systematic review of a combination of RCTs,
quasi-experimental and nonexperimental
studies, or nonexperimental studies only, with or
without meta- analysis

■

■

Qualitative study or meta- synthesis

2.

Exploratory, convergent, or multiphasic mixedmethods studies

■

Explanatory mixed method design that includes
only a level III Quantitative study

■

3.

Lack of training for healthcare
providers. CGM is safe in
pregnancy when used in
conjunction with RGM. CGM is
beneficial as adjunctive glucose
management tool in pregnancy
(Polsk & Garcetti, 2017).
CGM can effectively be used in
patients using MDI or CSII. TIR
has been standardized as 70-180
mg/dl and is established as a
specific target range for
pregnancy. CGM use is corelated
with a reduction of DM
complications. (Gabbay, et. al,
2020).
82 women completed the study
which demonstrated the
physiological importance of tight
glycemic control in minimizing
perinatal complications. CGM in
pregnancy identified significant
daily glucose variability otherwise
missed by standard care (SMBG).
(Mazze, et. al., 2012).
Observational cohort study.
CGM’s role in improving TIR,
improved fetal outcomes. LGA is
semester specific. Lower A1c in
first trimester, with higher BG
variability and less TIR associated
with LGA (Kristensen, et. al.,
2019).
Reduced in-person clinic visits d/t
CGM and RGM lowers costs.
HbA1c is naturally lower by 0.5%
during pregnancy d/t short
lifespan of RBC, increased
erythropoiesis. (Stewart, et. al.,
2019).
Explains the patho/physiology of
GDM, insulin resistance, glucose
intolerance, and metabolic
dysfunction as contributing factors
to variable blood glucose during
pregnancy. Cites ACOG and other
governing body guidelines and
recommendations, give extensive
background on CGM use and
benefits. (Carreiro, et. al., 2018).
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Category (Level Type)

Level IV
■

Total Number Overall
of Sources/
Quality
Level
Rating
2

Synthesis of Findings
Evidence That Answers the EBP
Question

B: Good Quality
A: Good Quality

1.

CGM was more helpful in
T1D. and demonstrated
postprandial hyperglycemia
and nocturnal hypoglycemia
that was either not evident or
underestimated by SBMG.
CGM improves clinical
decision-making; most
common change was
decreasing long-acting or
intermediate-acting insulin d/t
previously undetected
nocturnal hypoglycemia.
(Sung, Taslimi, & Faig, 2012).

2.

CGM training should be
made widely available to
clinicians such as nurses
and NPs, Formal
certification would add to
more barriers and isn’t
necessary. Clinician
training should be
expanded. (Fonseca, et. al,
2016).

Opinions of respected authorities and/or
reports of nationally recognized expert
committees or consensus panels based on
scientific evidence

Level V
■

■

Evidence obtained from literature or
integrative reviews, quality improvement,
program evaluation, financial evaluation,
or case reports
Opinion of nationally recognized expert(s)
based on experiential evidence

Recommendations based on evidence synthesis and selected translation pathway
Evidence is compelling and strong that registered nurses should be trained on CGM device technology. Specialized certification is not
necessary and is a barrier to expanding the use of CGM during pregnancy. With training, registered nurses work within their scope to use
CGM device technology in their work when caring for this population. Recommendation to conduct a pilot study to test implementation of a
new protocol to be used by registered nurses to titrate insulin dosages for women using CGM as adjunct therapy to multiple daily injections to
control diabetes during pregnancy. The implementation site is appropriate to test this pilot, is compatible with the cultural values and norms as
recommended by industry experts, is consistent with practices of the unit and organizational priorities. The implementation pilot is feasible and
has stakeholder support, funding, resources, and approval from unit leadership.

53

Appendix B
GAP ANALYSIS
Best Practice

Institution Practice

Barriers to Best

Will Implement Best

Strategy

Strategy

Practice

Practice (Yes/No;

Implementation

why not?)

Best Practice #1
Continuous Glucose

No RPSC CGM

Management and

Monitoring and

Program Exists

Leadership Support

RN Chronic Disease

New Hire Policy and

CNA Union Contract

Management

Procedure Training

and RN staff may

Yes

Diabetes
Management
Program
Best Practice #2

Education and
Training

lack support

Yes
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Appendix C
GANTT
2020
Task
Discuss Project
Project
Approval
Design
Training
Modules
Analyze
Qualtrics
Result
Present Results
Discuss Pilot
Pilot Approval

Assigned to
DNP
Candidate
Management
DNP
Candidate
DNP
Candidate
DNP
Candidate
DNP
Candidate
Management
and
Leadership

Pilot
RN Staff
Implementation
DNP
Final Qualtrics Candidate
Analyze Final
Qualtrics
Present
Findings

DNP
Candidate
DNP
Candidate

Jan

Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
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Appendix D
SWOT ANALYSIS
STRENGTHS

WEAKNESSES

•

Continuity of care

•

Less patient compliance

•

Increased patient safety

•

Unprecedented project proposal

•

Convenience of TAV

•

Increased patient census

•

16-hour unit support

•

SMART Goals

•

Numerous supporting evidences in
literature
OPPORTUNITIES

THREATS

•

Reduce clinic visits

•

RN resistance

•

Interdisciplinary Teamwork

•

Lack of Sponsor support

•

Vulnerable population

•

Provider resistance

•

Utilize EBP standards

•

Competing subspecialty units
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Appendix E
Work Breakdown Structure

LEVEL 1
1 Postpartum Diabetes
Management

LEVEL 2
1.1 Initiation

1.2 Planning

1.3
Execution

1.4 Control

1.5 Closeout

LEVEL 3
1.1.1 Evaluation and Recommendation
1.1.2 Discuss Project Charter
1.1.3 Deliverable: Project Charter
Submission
1.1.4 Sponsor Charter Review
1.1.5 Signed/Approved Project Charter
1.2.1 Preliminary Scope Statement
1.2.2 Project Team Selection
1.2.3 Project Plan Kickoff Meeting
1.2.4 Project Plan Development
1.2.5 Project Plan Submission
1.2.6 Milestone: Project Plan Approval
1.3.1 Project Kickoff Meeting
1.3.2 RN Requirements Verify/Validation
1.3.3 Policy & Procedure Design
1.3.4 Deliverable: P&P Submission
1.3.5 Sponsor P&P Review
1.3.6 Signed/Approved P&P
1.3.7 RN P&P Training
1.3.8 Go Live (Pilot)
1.4.1 Project Management
1.4.2 Project Status Meeting
1.4.3 Risk Management
1.4.4 Update Project Management Plan
1.5.1 Procurement Audit
1.5.2 Lessons Learned Session
1.5.3 Update Files
1.5.4 Gain Formal Acceptance
1.5.5 Archive Files

57

Appendix F
Proposed Budget
Estimated Cost

Material/Resources

$77.00 (36)

RN Paid Training: 1 hour

$0

Pretest (Qualtrics)

$0

Posttest (Qualtrics)

$0

Pretest (Qualtrics)

$0

Posttest (Qualtrics)

$0

Conference Room Reservation

$2772

Total
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Appendix G

Doctor of Nursing Practice
Statement of Non-Research Determination (SOD) Form
The SOD should be completed in NURS 7005 and NURS 791E/P or NURS 749/A/E

General Information
Last Name:

Beamish

First Name:

Nicole

CWID Number:

20381945

Semester/Year:

Summer 2019

Course Name &
Number:

N7005 Population Health Leadership and Teamwork in Project Planning

Chairperson
Name:

Dr. Loomis

Advisor Name:

Dr. Loomis

Project Description
1. Title of Project
Remote Glucose Monitoring and Continuous Glucose Monitoring Blood Glucose Report Interpretation in
a Regional Perinatal Service Center staffed by nurses in a telehealth setting
2. Brief Description of Project
Clearly state the purpose of the project and the problem statement in 250 words or less.
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The purpose of the project is to educate perinatal nurses on continuous glucose monitoring (CGM), remote
glucose monitoring (RGM), and blood glucose (BG) report interpretation for women with gestational and
chronic diabetes.
This is a major nursing practice change that will educate the nurses on CGM, RGM, and BG report
interpretation using Medtronic CareLink and Dexcom Clarity platforms. For 18+ years, the nursing staff have
titrated insulin for women during pregnancy using a strict protocol. Nurses do not currently titrate insulin for
pump users because they do not have insulin pump certification, and most nurses at the service center don't
know how to interpret the CGM reports.

3. AIM Statement: What are you trying to accomplish?
Complete this statement:
To increase the knowledge of nurses providing care to pregnant women referred using continuous
glucose monitoring, remote glucose monitoring, and blood glucose report interpretation
(process/outcome) from 0% (baseline %, rate, #, etc.) to 100% (goal/target %, rate, #, etc.) by 3 months
(date, 3 - 6-month timeframe) for registered nurses at the implementation unit (population impacted).
4 Brief Description of Intervention (150 words).

The intervention will be the creation of a CGM and RGM report interpretation algorithm that will allow the
registered nurses to feel confident titrating insulin dosages. The new algorithm will be based on an existing
algorithm of a 10% or 20% maximum insulin titration that relies upon the patient’s current BMI, hypoglycemic
history, gestational age, and current insulin dosages.
4a. How will this intervention be implemented?
• Where will you implement the project?
•

Attach a letter from the agency with approval of your project.

•

Who is the focus of the intervention?

•

How will you inform stakeholders/participants about the project and the intervention?

A pre-education survey will be given to the registered nurses to measure their confidence, knowledge, and degree
of education needed to effectively implement the algorithm.
The project will be implemented at the implementation unit in Northern California.
The focus of the intervention are the registered nurses.
The stakeholders and participants will be informed about the project and the intervention by the project leader,
unit director, unit manager, and department medical director the Northern California Region Perinatologists’
monthly meeting.
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5. Outcome measurements: How will you know that a change is an improvement?
• Measurement over time is essential to QI. Measures can be outcome, process, or balancing
measures. Baseline or benchmark data are needed to show improvement.
•

Align your measure with your problem statement and aim.

•

Try to define your measure as a numerator/denominator.
o What is the reliability and validity of the measure? Provide any tools that you will use as
appendices.
o Describe how you will protect participant confidentiality.

Outcome measurements will be based on the post-education surveys given to the registered
nurses and compared to the pre-education surveys to determine if an increase in nurse competence and
knowledge exists within 3 months of implementation, with a goal of 100% of the nurses reporting an
increase in competence, confidence, and knowledge of CGM, RGM, and BG report interpretation.
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DNP Statement of Determination
Evidence-Based Change of Practice Project Checklist*
The SOD should be completed in NURS 7005 and NURS 791E/P or NURS 749/A/E

Project Title:
Remote Glucose Monitoring and Continuous Glucose Monitoring Blood Glucose Report Interpretation in
a Regional Perinatal Service Center staffed by nurses in a telehealth setting

Mark an “X” under “Yes” or “No” for each of the following statements:

Yes

The aim of the project is to improve the process or delivery of care with established/ accepted
standards, or to implement evidence-based change. There is no intention of using the data for
research purposes.

X

The specific aim is to improve performance on a specific service or program and is a part of
usual care. All participants will receive standard of care.

X

The project is not designed to follow a research design, e.g., hypothesis testing or group
comparison, randomization, control groups, prospective comparison groups, cross-sectional,
case control). The project does not follow a protocol that overrides clinical decision-making.

X

The project involves implementation of established and tested quality standards and/or
systematic monitoring, assessment or evaluation of the organization to ensure that existing
quality standards are being met. The project does not develop paradigms or untested methods
or new untested standards.
The project involves implementation of care practices and interventions that are consensusbased or evidence-based. The project does not seek to test an intervention that is beyond
current science and experience.

X

The project is conducted by staff where the project will take place and involves staff who are
working at an agency that has an agreement with USF SONHP.

X

The project has no funding from federal agencies or research-focused organizations and is not
receiving funding for implementation research.

X

The agency or clinical practice unit agrees that this is a project that will be implemented to
improve the process or delivery of care, i.e., not a personal research project that is dependent
upon the voluntary participation of colleagues, students and/ or patients.

X

If there is an intent to, or possibility of publishing your work, you and supervising faculty and the
agency oversight committee are comfortable with the following statement in your methods
section: “This project was undertaken as an Evidence-based change of practice project at X
hospital or agency and as such was not formally supervised by the Institutional Review Board.”

X

X

No
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Answer Key:
•

If the answer to all of these items is “Yes”, the project can be considered an evidence-based activity
that does not meet the definition of research. IRB review is not required. Keep a copy of this checklist
in your files.

•

If the answer to any of these questions is “No”, you must submit for IRB approval.

*Adapted with permission of Elizabeth L. Hohmann, MD, Director and Chair, Partners Human Research Committee,
Partners Health System, Boston, MA.

To qualify as an Evidence-based Change in Practice Project, rather than a Research Project, the criteria
outlined in federal guidelines will be used: http://answers.hhs.gov/ohrp/categories/1569

DNP Statement of Determination
Evidence-Based Change of Practice Project Checklist Outcome
The SOD should be completed in NURS 7005 and NURS 791E/P or NURS 749/A/E

Project Title:
Remote Glucose Monitoring and Continuous Glucose Monitoring Blood Glucose Report Interpretation
in a Regional Perinatal Service Center staffed by nurses in a telehealth setting

☑ This project meets the guidelines for an Evidence-based Change in Practice Project as outlined in the
Project Checklist (attached). Student may proceed with implementation.
☐ This project involves research with human subjects and must be submitted for IRB approval before
project activity can commence.

Comments: This project will not require IRB approval because no human subjects are needed to

develop the nursing education protocol.

Student
Last Name:

Beamish

Student
First Name:

Nicole

CWID Number:

20381945

Semester/
Year:

Fall 2019

Student
Signature:

Nicole L. Beamish

5/228/2020
Date:
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Chairperson
Name:
Chairperson
Signature:

Jo Loomis
9/27/20
Jo Loomis

Date:

DNP SOD Review
Committee
Member Name:
DNP SOD Review
Committee
Member
Signature:

Date:
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Appendix H
Communication Plan/Matrix
Communication

DNP Candidate

Leadership

Management

Matrix
Update

Registered
Nurses

Daily

N/A

N/A

Daily

Will Provide

Advise

Advise

Will Receive

Responsible

Advise

Advise

N/A

N/A

N/A

Will Approve

N/A

Implement Pilot

Project Manager

N/A

Advise

N/A

Call Patients to

N/A

N/A

N/A

Responsible

N/A

N/A

N/A

Responsible

Communication
Board
Conduct Staff
Training
Analyze
Qualtrics
Pay Staff for
Training

collect data
Call Patients for
dietary consult
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Appendix I
Qualtrics Pre-Education and Training Survey
Strongly

Disagree

Undecided

Agree

Disagree
1

Strongly
Agree

2

3

4

5

Answer the following questions using the scale above.
1. I am familiar with the term,” Continuous Glucose Monitoring”.
2. I have had at least one patient using CGM assigned to the desk I have been
working on this year.
3. I feel confident providing care to patients using CGM.
4. For patients using CGM, I titrate insulin for the patient and route the report to the
provider afterwards.
5. For patients using CGM, I collect blood glucose only then route the blood glucose
report to the provider for a new insulin titration order.
6. I would participate if offered training on CGM.
7. If CGM training included blood glucose and CGM report interpretation, I would
feel confident titrating insulin dosages for patients using CGM.
.
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CGM Training Modules
Appendix J
Module 1

•
•

Module 3

•
•
•

Module 4

•

Module 2

Review Medtronic Guardian CGM device and CareLink
software
Review Dexcom G6 CGM device and Clarity software
o Terminology
o Blood glucose report selection
o Blood glucose report interpretation
CGM documentation
CGM Communication and Data Sharing
New NP-developed insulin titration protocol
o For patients using multiple daily injections
Case study
o Accurately identify pertinent information
o Implementation of new insulin titration protocol
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Appendix K
Provider-developed Insulin Titration Protocol
The table below shows the recommended values for glucose targets.
Fasting
Preprandial
1-hour Postprandial from beginning of food intake
2 am – 3 am

Plasma Glucose Goals
60-90 mg/dL
60-100 mg/dL
<130 mg/dL
>60 mg/dL

If inadequate control is reflected by two or more elevated fasting (>95 mg/dL) in one week or
two or more elevated 1-hour postprandial glucose (>140 mg/dL) in one week, despite dietary and
exercise compliance, the following medication guidelines will apply.
Assessment
A. Understanding all adherence to diet, exercise recommendations.
B. Ongoing knowledge and understanding of pregnancy process complicated by diabetes
during pregnancy.
C. Adherence with insulin regimen.
D. Review of any signs or symptoms of hypo- and hyperglycemia.
Planning
A. Log onto CGM device platform.
B. Review CGM trending and Time in Range reports with patients using CGM technology
during pregnancy.
C. CGM reports will be documented in the patient’s chart and routed to the provider for
review.
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Intervention and Evaluation
A. Severely elevated fasting blood glucose: CGM report evaluation of fasting blood glucose
is >110 mg/dL for 2 days, patient will notify the registered nurse. The registered nurse
will evaluate for obvious etiology. If elevation for 2 or more, refer to medication
management.
B. Moderately elevated fasting blood glucose: CGM report evaluation of fasting blood
glucose is 95-110 mg/dL for 2 days, registered nurse will verify adherence to diet and
exercise recommendations. If patient has been adhering to diet and exercise
recommendations, refer to provider for further evaluation or follow medical management.
If patient has not been adhering to diet and exercise recommendations, nurse will discuss
methods to improve adherence and develop a plan agreed upon by the patient.
C. Elevated postprandial glucose: if CGM report evaluation of 1-hour postprandial is >180
the registered nurse will verify adherence to diet and exercise recommendations. If
patient has been adhering to diet and exercise recommendations, refer to provider for
further evaluation or follow medication management. If patient has not been adhering to
diet and exercise recommendations, the registered nurse will discuss methods to improve
adherence and develop a plan agreed upon by the patient.
Medication Management
A. Adjust insulin dosages based on the following guidelines unless patient can attribute
abnormal CGM reported values to dietary changes or illness.
B. For patients with long-acting insulin such as Lantus, refer to primary provider for dosage
adjustment.
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C. Based on the current protocol, registered nurses can increase rapid acting, short or
intermediate insulin to a maximum of 18 units. If a higher dose is necessary, the primary
obstetrical or maternal fetal medicine provider must be consulted.
D. Total insulin dose change should not exceed 20% of the previous insulin dose, unless
orders for a greater percent change has been obtained and documented in the patient’s
chart. Any increase should be rounded up to the next even increment.
E. Prior to an insulin increase of 20%, verify any previous history of nocturnal
hypoglycemia. If patient has a history of hypoglycemia or nocturnal hypoglycemia,
increase insulin to a maximum of 10% or consult with the primary obstetrical or maternal
fetal medicine provider.
F. Post insulin increase of 20%, the registered nurse will instruct the patient to conduct a
safety check at 3 am or endure CGM hypoglycemia alarms are set appropriately.
Note: Adapted from “Patient Care Guidelines: Home Management Insulin Requiring Diabetes
Policy” by Regional Perinatal Service Center, 2019.
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Appendix L
CGM Modules 1-4
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Note: CGM During Pregnancy Education Modules 1-4, 2020.
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Appendix M

Continuous Glucose Monitoring During Pregnancy: Post-Education and
Training Survey
Start of Block: Default Question Block
Q1 Since completing the Continuous Glucose Monitoring and Diabetes Management During Pregnancy
education and training modules, I feel competent with professional documentation in the EHR.
______ Not at all (1)
______ Somewhat (2)
______ Completely competent (3)
Q2 I have cared for patients using Continuous Glucose Monitoring and Diabetes Management During
Pregnancy before the CGM education and training modules.

o Not at all (1)
o Almost never (2)
o Some of the time (3)
o Most of the time (4)
o All of the time (5)
Q3 Since completing the CGM education and training modules, my knowledge of Continuous Glucose
Monitoring and Diabetes Management During Pregnancy has increased.

o Not at all (1)
o A minor amount (2)
o A moderate amount (3)
o A significant amount (4)
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Q4 The CGM module education level was appropriate for my learning.

o Not at all (1)
o Somewhat (2)
o I Completely agree (3)
Q5 The CGM module education utilized graphics and provided transcripts that enhanced my learning.

o Not at all (1)
o Somewhat (2)
o A moderate amount (3)
o I completely agree (4)
Q6 After completing the CGM modules, I feel competent providing care for patients using multiple daily
injections and CGM as adjunctive therapy.

o Extremely competent (1)
o Moderately competent (2)
o Slightly competent (3)
o Neither competent nor incompetent (4)
o Slightly incompetent (5)
o Moderately incompetent (6)
o Extremely incompetent (7)
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Q7 After completing the CGM education and training modules, I have a clear understanding of the NPDeveloped CGM Insulin Titration Protocol.

o Not at all (1)
o Some understanding (2)
o Complete understanding (3)
Q8 After completing the CGM education and training modules, I feel competent providing care to users
of CGM technology and using the NP-Developed CGM Insulin Titration Protocol.

o Extremely competent (1)
o Moderately competent (2)
o Slightly competent (3)
o Neither competent nor incompetent (4)
o Slightly incompetent (5)
o Moderately incompetent (6)
o Extremely incompetent (7)
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Q9 After completing the CGM education and training modules, I feel confident answering my patient's
questions of CGM technology and use during pregnancy.

o Extremely confident (1)
o Moderately confident (2)
o Slightly confident (3)
o Neither competent nor incompetent (4)
o Slightly incompetent (5)
o Moderately incompetent (6)
o Extremely incompetent (7)
Q10 After completing the CGM education and training modules, I will seek CGM Certification to further
enhance my learning.

o Not at all likely (1)
o Somewhat likely (2)
o Moderately likely (3)
o Highly likely (4)
o Definitely (5)
End of Block: Default Question Block

Note: CGM During Pregnancy and Diabetes Management Qualtrics Post-Education Survey,
2020, https://usfca.qualtrics.com/Q/EditSection/Blocks?SurveyID=SV_9GgRuejGUWBKG6V.
In the public domain.
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Table 1
Provider-developed Insulin Titration Protocol

Plasma
Fasting/Pre-breakfast
Mean BG
< 60

Mean BG
Mean BG

60-95
96-110

Mean BG

>110

1 hour after breakfast
Mean BG
<130
Mean BG
130-160

Mean BG

1 hour after lunch
Mean BG
Mean BG

Mean BG

>160

<130
130-160

>160

Insulin Adjustment
BMI < 29
BMI >/= 29
Decrease evening or HS
NPH by 20% or a
minimum of 2 units
No change in NPH
Increase evening or HS
NPH by 10%
Increase evening of HS
NPH by 20%

Decrease evening or HS
NPH by 20% or a
minimum of 2 units
No change in NPH
Increase evening of HS
NPH by 20%
Increase evening of HS
NPH by 20%

No change
Increase pre-breakfast
Regular by 10% or
increase Rapid-acting
insulin at breakfast by
10%
Increase pre-breakfast
Regular by 20% or
increase Rapid-acting
insulin at breakfast by
20%

No change
Increase pre-breakfast
Regular by 20% or
Increase Rapid-acting
insulin at breakfast by 20%

No Change
Increase pre-breakfast
NPH by 10% or Increase
pre-lunch Regular by
10% or increase Rapidacting insulin at lunch by
10%
Increase pre-breakfast
NPH by 20% or Increase
pre-lunch Regular by
20% or increase Rapidacting insulin at lunch by
20%

No Change
Increase pre-breakfast
NPH by 20% or Increase
pre-lunch Regular by 20%
or increase Rapid-acting
insulin at lunch by 20%

Increase pre-breakfast
Regular by 20% or
Increase Rapid-acting
insulin at breakfast by 20%

Increase pre-breakfast
NPH by 20% or Increase
pre-lunch Regular by 20%
or increase Rapid-acting
insulin at lunch by 20%
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Pre-Dinner
Mean BG

<60

Mean BG
Mean BG

60-110
111-130

Mean BG

>130

1 hour after dinner
Mean BG
Mean BG

Mean BG

<130
130-160

>160

Decrease Pre-breakfast
NPH by 20% or a
minimum of 2 units or
add CHO exchange to
afternoon snack
No change in NPH
Increase pre-breakfast
NPH by 10% or Increase
Pre-dinner Regular
insulin by 10% or
Increase Rapid-acting
insulin at dinner by 10%
Increase pre-breakfast
NPH by 20% or Increase
Pre-dinner Regular
insulin by 20% or
Increase Rapid-acting
insulin at dinner by 20%

Decrease Pre-breakfast
NPH by 20% or a
minimum of 2 units or add
CHO exchange to
afternoon snack
No change in NPH
Increase pre-breakfast
NPH by 20% or Increase
Pre-dinner Regular insulin
by 20% or Increase Rapidacting insulin at dinner by
20%
Increase pre-breakfast
NPH by 20% or Increase
Pre-dinner Regular insulin
by 20% or Increase Rapidacting insulin at dinner by
20%

No change
Increase Pre-breakfast
NPH by 10% or Increase
Pre-dinner Regular
insulin by 10% or
Increase Rapid-acting
insulin at dinner by 10%
Increase Pre-breakfast
NPH by 20% or Increase
Pre-dinner Regular
insulin by 20% or
Increase Rapid-acting
insulin at dinner by 20%

No change
Increase Pre-breakfast
NPH by 20% or Increase
Pre-dinner Regular insulin
by 20% or Increase Rapidacting insulin at dinner by
20%
Increase Pre-breakfast
NPH by 20% or Increase
Pre-dinner Regular insulin
by 20% or Increase Rapidacting insulin at dinner by
20%

Note: Adapted from “Patient Care Guidelines: Home Management Insulin Requiring Diabetes
Policy” by Regional Perinatal Service Center, 2019.
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Table 2
ADA Recommended Pregnancy Guidelines by Diabetes Type
Variable

Gestational Diabetes
(GDM)
Fasting: <95 mg/dL
One-hour postprandial
glucose: <140 mg/dL
Two-hour postprandial
glucose: <120 mg/dL

Type 2 Diabetes
(DM2)
Fasting: <95 mg/dL
One-hour
postprandial glucose:
<140 mg/dL
Two-hour
postprandial glucose:
<120 mg/dL
Preprandial Testing

Type 1 Diabetes
(DM1)
Fasting: <95 mg/dL
One-hour
postprandial glucose:
<140 mg/dL
Two-hour
postprandial glucose:
<120 mg/dL
Preprandial Testing

Medical
Nutritional
Therapy (DRI)

175 g carbohydrate, 71
g protein, 28 g fiber

175 g carbohydrate,
71 g protein, 28 g
fiber

175 g carbohydrate,
71 g protein, 28 g
fiber

Pharmacologic
Therapy

Oral antihyperglycemic;
Insulin is first line
treatment

Metformin until 12
weeks GA, then
glyburide or insulin

Insulin by multiple
daily injections or
insulin pump therapy

Education

Lifestyle management,
glucometer use

Lifestyle
management,
glucometer use,
pharmacologic
therapy, prevention
of hypoglycemia

Risk of Pregnancy
Loss
HbA1c

Comparable to that of
normal pregnancy
<6%

Highest in third
trimester
<6% or <7% to
prevent
hypoglycemia

Lifestyle
management,
glucometer and
insulin pump use,
continuous glucose
monitor use,
prevention of
hypoglycemia
Highest in first
trimester
<6% or <7% to
prevent
hypoglycemia

Blood Glucose
Goals

Note: Recommended diabetes guidelines for pregnancy by diabetes type. From “Management of
Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2019” by American Diabetes
Association, 2019, https://www.care.diabetesjournals.org/content/42/Supplement_1/S165. In the public
domain.
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Table 3
CGM Device Comparison

Note: Comparison of the Dexcom G6 continuous glucose monitoring device and the Medtronic
Guardian continuous glucose monitoring device. Left panel: Dexcom G6 CGM information.
From “How it Works”, by Dexcom Continuous Glucose Monitoring, 2020,
https://www.dexcom.com/g6/how-it-works. Copyright 2020 by Dexcom Continuous Glucose
Monitoring. Right panel: Medtronic Guardian CGM information. From “Continuous Glucose
Monitoring”, by Medtronic, 2020, https://www.medtronicdiabetes.com/treatments/continuousglucose-monitoring. Copyright 2020 by Medtronic. In the public domain.
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Figure 1
CGM Software Comparison
Dexcom Clarity

Note: A sample of the Dexcom Clarity Diabetes Management Software showing blood glucose
ranges over a 2-day period. Adapted from 2020 Dexcom Clarity Diabetes Management Software
Products, by Dexcom, 2020 https://www.dexcom.com/clarity.
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Figure 2
CGM Software Comparison
Medtronic CareLink

Note: A sample of the Medtronic Carelink Personal software showing blood glucose data from a
continuous glucose monitor and glucometer over a 2-week period. Adapted from 2020 Carelink
Personal Diabetes Software Products, by Medtronic, 2020
https://www.medtronicdiabetes.com/products/carelink-personal-diabetes-software. In the public
domain.
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Figure 3
Lewin’s Theory of Change

Note: Lewin’s Theory of Change. Unfreezing: Initial needs assessment identified gap in
nursing education on CGM technology and delay in care for patients who use CGM during
pregnancy Change in Practice: Education modules provided to registered nurses on CGM
technology and the NP-developed protocol for titrating insulin Refreezing: Positive response
from CGM education modules equipped registered nurses’ utilization of the NP-developed
protocol to guide clinical decision-making, no longer delaying care waiting for a new insulin
order from the provider.

83

Figure 4
CGM Post-Education Survey Data

Note: CGM During Pregnancy and Diabetes Management Post-Education Survey, 2020.
66.67% of respondents completely agreed the CGM education level was appropriate for
their learning, while 33.33% felt it was somewhat appropriate for their learning.
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Figure 5
CGM Post-Education Survey Data

Note: CGM During Pregnancy and Diabetes Management Post-Education Survey, 2020.
Since completing the CGM education and training modules, 33% or respondents reported
an increase in knowledge of CGM and diabetes management a significant amount, a
moderate amount, and a minor amount.
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Figure 6
Hemoglobin A1c Comparison

Note: The Hemoglobin A1c chart shows patients with their starting HbgA1c in blue and the
final HgbA1c in orange. All but one patient showed a decrease in HgbA1c at the end of the
pilot or at delivery.

